DiaSorin SpA
Angelo Rago is currently the new President of Luminex Corporation, with a 30+ years’ experience in top-level positions at global MedTech companies.
Prior to this role, he was President of Carl Zeiss Meditec, Inc. and the Global Head of Ophthalmic Diagnostics (ODx). He has spent this time of his career developing and marketing new medical technologies around the world. Prior to joining ZEISS, Angelo Rago held various management positions at Abbott Medical Optics (AMO) for seven years. He also spent 17 years with Siemens Medical Solutions, in senior positions in the areas of service and product development, culminating to VP of Global Customer Services – Oncology Division.
Angelo Rago holds a Bachelor's degree in Mechanical Engineering and an Executive Certification in Innovation & Strategy from MIT's Sloan School of Business.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.